Overall principles: AS is a disease with multiple clinical manifestations and potentially serious consequences that requires multidisciplinary treatment coordinated by a rheumatologist. the primary treatment goals for AS are to maximize quality of life by controlling symptoms and inflammation, avoiding long-term joint deformities, and maintaining social competence. the goal of AS treatment is to provide the best possible care for the patient with shared decision making between the physician and the patient, taking into account The aim of AS treatment is to provide the best care for the patient under the joint decision of the physician and the patient, taking into account both pharmacological and non-pharmacological treatments. 1. General treatment: Treatment of AS needs to be based on the existing clinical phenotype (including mid-shaft, peripheral joint and tendon end lesions, extra-articular symptoms and signs); the severity of existing symptoms, clinical presentation and prognosis; and general clinical characteristics (age, gender, comorbidities, combined medications and psychosocial factors). 2.Disease monitoring: including medical history (e.g., questionnaire), clinical parameters, laboratory tests, imaging, and specific monitoring time according to disease duration, severity and individualization of treatment. 3.Non-pharmacological treatment: its basis is patient education and regular exercise. Home exercise is very effective, while physiotherapy, individual or group exercise on land or in water under special guidance is more effective. Patient associations or self-help groups may be beneficial. 4. Extra-articular manifestations and complications: Common extra-articular manifestations such as psoriasis, uveitis and inflammatory bowel disease require collaborative treatment with a specialist. 5. Non-retaining anti-inflammatory drugs: NSAIDs, including celebrex, are the first-line agents for the treatment of patients with AS who have pain and morning stiffness. Patients with active disease and clinical symptoms require continuous treatment with NSAIDs. Cardiovascular, gastrointestinal and renal risks should be considered when prescribing NSAIDs. 6, analgesics: such as paracetamol and opioids, can be given to patients for whom prior therapy has not been effective or is contraindicated or has poor efficacy. 7, glucocorticoids: can be injected directly at the inflammation of the muscle bone exclusion. There is no evidence to support the systemic application of glucocorticoids for medial lesions. DMARDs: There is no conclusive evidence for the treatment of mid-axis lesions with DMARDs, including salbutamol and methotrexate. Salazosulfonamide la? has been shown to be effective in the treatment of peripheral joints. 9. Anti-TNF therapy: Patients receiving conventional therapy recommended by ASAS but with persistently high disease activity should be treated with anti-TNF therapy. There is no evidence to support the application or combination of DMARD in patients with mid-axis SpA before receiving anti-TNF therapy. There is no significant difference in the efficacy of various TNF inhibitors for mesial or peripheral SpA, but the difference in efficacy of various TNF inhibitors needs to be considered for intestinal symptoms in patients with IBD. For one anti-TNF therapy that is ineffective, replacement with a second one may still be effective. There is no evidence to support the effectiveness of biological agents other than anti-TNF for the treatment of AS. 10. Surgery: Total hip arthroplasty is suitable for patients with AS whose imaging suggests structural destruction with refractory pain or loss of function, and corrective spinal osteotomy can be performed for patients with severe spinal deformities with limited motion. Patients with acute vertebral fractures need to be seen by a spine surgeon. 11. Changes in the course of the disease: Special changes in the course of the disease, such as spinal fractures in addition to inflammation, require attention and re-evaluation.